However, in terms of diagnostic utility, BRAF, NRAS, and TERT promoter mutations have shown greater potential due to the high prevalence and clinical features in thyroid cancer (Liu et al., 2012; Moses et al., 2010; Nikiforov et al., 2009). This evidence concerns the gene NRAS and thyroid cancer.